The final Scientific Meeting of 2024 was held in November. Four concepts were presented, spanning both advanced oncogene-driven NSCLC populations and a neoadjuvant immunotherapy concept. Two of the four concepts were approved for further development.
Key Highlights 2024
- 23 concepts were submitted for review by working groups. All these concepts were also reviewed by patient representatives that are part of the working groups or Scientific Committee.
- 15 of these concepts were recommended to the Scientific Committee.
- The committee approved 13 for further development.
- Six of these are concepts that already have funding and can progress without further grant funding.
- The remaining seven have been submitted or intend to submit for grant funding.
- Of the remaining seven:
- Two concepts have been unsuccessful and are searching for further funding options
- Two are yet to be submitted
- Three are awaiting outcomes
Overall, this year has seen the highest number of concept submissions.
Acknowledgments
We thank all those who submitted concepts, and all TOGA members who have joined the Scientific Committee and the working groups to review the submissions. Peer and consumer-review is a critical component of TOGA’s research program to ensure high-quality, feasible, and relevant research in thoracic cancers.
Additional Information
If you have any questions about the Scientific Meeting or any of the concepts that were presented, please contact the TOGA office at info@thoraciconcology.org.au
